Free Newsletter
Specialty drugmakers lobbying together
Here's a quandary: You're a good-sized drugmaker, but not a behemoth able to throw your weight around the industry's big trade associations. So how do you get your voice heard in our nation's capital? Form your own association, of course. That's exactly what Celgene, Cephalon, Cubist, Endo, Millennium, Purdue and Sepracor are doing: Banding together under the name America's Specialty Medicines Companies, and hiring a D.C. law firm for help getting organized.
What might this assortment's key issues be? That's unclear as yet. But you can bet we'll hear more from them as time goes by.
- read the item at In Vivo
Related Articles:
Dems swayed by pharma lobbying push
PhRMA plows $22M into 2007 lobbying
Millennium spent $1.3M on lobbying
Pharma lobbies big-time in '07
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: